References
- Anagnostis P, Vaitsi K, Mintziori G, et al. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. Curr Med Res Opin. 2020;36(5):731–740.
- Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS guidelines: section a – prevention in patients with carotid stenosis. Curr Vasc Pharmacol. 2010;8(5):673–681.
- Naylor AR, Ricco JB, de Borst GJ, et al. Editor’s choice – management of atherosclerotic carotid and vertebral artery disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55:3–81.
- Iyen B, Qureshi N, Kai J, et al. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study. Atherosclerosis. 2019;287:8–15.
- Wang X, Cai G, Wang Y, et al. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids Health Dis. 2019;18(1):131.
- DeRubertis BG, Faries PL, McKinsey JF, et al. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg. 2007;246(3):415–422.
- Katsiki N, Giannoukas AD, Athyros VG, et al. Lipid-lowering treatment in peripheral artery disease. Curr Opin Pharmacol. 2018;39:19–26.
- Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral arterial disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338–350.